On 10 February 2021, the European Commission accepted commitments from Aspen under Article 9(1) of Regulation 1/2003, concluding a three year investigation into suspected excessive pricing practices affecting six critical cancer medicines. What you need to know - key takeawaysThe Commission based its assessment of pricing levels on the absolute and relative profitability of the medicines; considering Aspen's costs as well as profit levels of other similar businesses in the pharmaceutical industry.The Commission also considered the lack of potential justifications for price and profit levels; in this case
The EU Commission accepts commitments from a pharmaceutical company to address excessive pricing (Aspen)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.